Last Update

This profile was last updated on 11/26/2017 and contains contributions from the  ZoomInfo Community.

is this you? Claim your profile.

Wrong Geraldine Henwood?

Geraldine A. Henwood

President and Chief Executive Officer

Recro Pharma, Inc.

HQ Phone:  (484) 395-2470

Direct Phone: (484) ***-****direct phone

Email: g***@***.com

Get Zoominfo Grow
Community Edition

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    the Plugin
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check Your Inbox to
    Sign Up for ZoomInfo Community Edition

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Recro Pharma, Inc.

490 Lapp Road

Malvern, Pennsylvania, 19355

United States

Company Description

Recro Pharma is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post-operative pain. Recro Pharma is currently developing IV/IM meloxicam, a proprietary, long-acting preferential COX-...more

Find other employees at this company (112)

Web References(145 Total References)


Management Team :: Recro Pharma, Inc. (REPH)

Gerri Henwood
President & Chief Executive Officer Gerri Henwood has served as our President and Chief Executive Officer and a director of the Company since our inception in 2008. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Ms. Henwood continues to spend a very small portion of her time engaged in the provision of consulting services for MCG to other companies, including companies that are engaged in the development and commercialization of other pharmaceutical products. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc, in the pharmaceutical management program. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director-Marketing in the International Pharmaceutical Division. Ms. Henwood currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, a position she has held since May 2015, and two private companies, and she previously served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015. Ms. Henwood also serves on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc. Ms. Henwood holds a B.S. in Biology from Neumann University. As our founder and having served as a director since our inception, Ms. Henwood's extensive knowledge of our business and history, experience as a board member of multiple publicly-traded and privately-held companies, and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies, as well as Ms. Henwood's strong background in clinical and product development and substantial knowledge of the pharmaceutical industry, contributed to our Board's conclusion that she should serve as a director of our company. Ms. Myers is Ms. Henwood's sister.


Recro Pharma Secures $100 Million Credit Facility Nasdaq:REPH

"We are delighted to have the support and confidence of Athyrium, a premier partner known for its strategic investments in promising healthcare companies and assets," said Gerri Henwood, President and Chief Executive Officer of Recro Pharma.


Tetraphase Pharmaceuticals Appoints Gerri Henwood to Board of Directors | Directors and Boards

Tetraphase Pharmaceuticals Appoints Gerri Henwood to Board of Directors
Tetraphase Pharmaceuticals Appoints Gerri Henwood to Board of Directors Tetraphase Pharmaceuticals Appoints Gerri Henwood to Board of Directors Tetraphase Pharmaceuticals, Inc. announced the appointment of Gerri Henwood, President and Chief Executive Officer of Recro Pharma, to the Company's Board of Directors, according to a Globe News Wire press release. Henwood brings more than 30 years of experience in product commercialization, clinical development and regulatory approval processes to the board.


Board of Directors | Seachaid Pharmaceuticals

Gerri Henwood - Ms. Henwood is the President/CEO of Recro Pharma and is President/Founder of Malvern Consulting Group.
She was the President and CEO of Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL), a company she founded in late 1999. She raised $90 million in private equity and was able to take the company public in August 2004. Ms. Henwood successfully shepherded this start-up company through the drug development stage to its current position with one drug on the market and several more in late stage development and trailing 12 month revenues exceeding $60 million. From 1985-1999, Ms. Henwood was the founder and CEO of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998. Ms. Henwood began her career with Smith Kline & French, now part of Glaxo SmithKline PLC, in the pharmaceutical marketing department. She rose through the ranks at Smith Kline & French to be the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director - Marketing in the International Pharmaceutical Division.


Board of Directors | American Pain Association

Gerri Henwood
CEO & President, Recro Pharma, Inc


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory